Table 3

Summary of all treatment-related adverse events (N = 29)

Adverse eventNo. of patients by event grade
Total patients, n (%)
Grade 1Grade 2Grade 3Grade 4
Treatment-related in ≥ 25% of patients      
    Thrombocytopenia 24 (83) 
    Neutropenia (ANC/AGC) 11 23 (79) 
    Anemia 10 17 (59) 
    Leukopenia 10 17 (59) 
    Fatigue (asthenia, lethargy, malaise) 13 (45) 
    Diarrhea 10 (35) 
    Hypocalcemia 9 (31) 
    Hyperglycemia 9 (31) 
    Nausea 8 (28) 
Additional grades 3 or 4      
    Hypokalemia 6 (21) 
    Dehydration 2 (6) 
    Prolonged QTc interval 1 (3) 
    Arrhythmia, atrial fibrillation 1 (3) 
    Infection with normal (pneumonia) 1 (3) 
    Febrile neutropenia 1 (3) 
    Pain, joint 1 (3) 
Adverse eventNo. of patients by event grade
Total patients, n (%)
Grade 1Grade 2Grade 3Grade 4
Treatment-related in ≥ 25% of patients      
    Thrombocytopenia 24 (83) 
    Neutropenia (ANC/AGC) 11 23 (79) 
    Anemia 10 17 (59) 
    Leukopenia 10 17 (59) 
    Fatigue (asthenia, lethargy, malaise) 13 (45) 
    Diarrhea 10 (35) 
    Hypocalcemia 9 (31) 
    Hyperglycemia 9 (31) 
    Nausea 8 (28) 
Additional grades 3 or 4      
    Hypokalemia 6 (21) 
    Dehydration 2 (6) 
    Prolonged QTc interval 1 (3) 
    Arrhythmia, atrial fibrillation 1 (3) 
    Infection with normal (pneumonia) 1 (3) 
    Febrile neutropenia 1 (3) 
    Pain, joint 1 (3) 

ANC indicates absolute neutrophil count; and AGC, absolute granulocyte count.

Close Modal

or Create an Account

Close Modal
Close Modal